சுவாச பாதை தொற்று News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Significantly more patients with moderate-to-severe pemphigus sustained their complete remission with rituximab (Rituxan) than with mycophenolate mofetil (MMF), a randomized trial showed. At 1 year, 40% of patients treated with rituximab had sustained complete remission after ≥16 weeks off prednisone, as compared with 10% of patients randomized to MMF. Rituximab treatment was associated with a significantly reduced need for glucocorticoids and with a dramatic reduction in the number of disease flares. Quality-of-life scores improved more with rituximab, but MMF was associated with fewer serious adverse events (SAEs), reported Victoria Werth, MD, of the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues in the

United statesCharles bankheadUniversity of pennsylvania perelman school medicineInternational society for pharmacoeconomicsVictoria werthPennsylvania perelman schoolNew england journalInternational societyPemphigus disease area indexDermatology life quality indexMedpage todayEngland journalEnglj medPemphigus vulgarisRespiratory tract infectionஒன்றுபட்டது மாநிலங்களில்